Transmeta Corporation (NASDAQ: TMTA) today announced financial results
for the third quarter ended September 30, 2008.
Revenue for the third quarter of 2008 was $25.3 million, compared with
$366,000 for the second quarter of 2008. Revenue in both the third and
second quarters of 2008 was derived from licensing activities.
Total operating expenses for the third quarter of 2008 resulted in a
gain of $3.5 million, compared with expenses of $1.9 million in the
second quarter of 2008. Third quarter operating expenses included $2.9
million of income from two previously announced agreements with Intel
entered into during the quarter. Third quarter operating expenses also
included $5.9 million of income from the December 2007 settlement and
licensing agreement with Intel, and non-cash stock compensation charges
of $887,000.
In the third quarter, Transmeta recorded interest income of $1.8
million, including $1.2 million of imputed interest income from the
December 2007 settlement and licensing agreement with Intel. Net income
was $30.6 million, or $2.31 per share, compared with $214,000, or $0.02
per share, in the second quarter of 2008.
Transmeta’s cash, cash equivalents and short term investments at
September 30, 2008 totaled $255.2 million. Cash at September 30, 2008
included the $91.5 million payment received from Intel pursuant to the
technology licensing and amended settlement and licensing agreements
entered into in September 2008, as well as the $25 million payment from
NVIDIA for the licensing agreement it entered into in July 2008.
Transmeta continues to be debt free.
AMD Patent License
Transmeta also announced today that it has entered into a patent license
agreement with Advanced Micro Devices ("AMD”). The agreement grants a
non-exclusive license under Transmeta’s patents to AMD, and includes
FoundryCo, which AMD recently announced as part of its Asset Smart
strategy. Under the terms of the agreement, AMD will transfer to
Transmeta 700,000 shares of Transmeta’s Series B Preferred Stock held by
AMD. The 700,000 shares of Series B Preferred Stock are convertible into
499,429 shares of Transmeta’s common stock.
"We are pleased to have achieved this license agreement with AMD," said
Les Crudele, president and CEO of Transmeta. "Transmeta and AMD have a
long history of collaboration on promoting industry standards for
next-generation microprocessors, as well as a broader strategic
relationship. This licensing agreement further highlights the value of
Transmeta’s intellectual property and technologies to our industry, and
provides Transmeta stockholders with an immediate return on our
intellectual property rights."
Acquisition By Novafora, Inc.
Transmeta also announced in a separate release today that it signed a
definitive agreement to be acquired by Novafora, Inc. for $255.6 million
in cash, subject to certain working capital and other adjustments.
Novafora is a privately held fabless semiconductor company in San Jose,
California that develops a family of digital video processors. Under the
terms of the agreement, and based on current estimates of Transmeta’s
future working capital at the effective time of the merger, stockholders
are expected to receive between $18.70 and $19.00 for each outstanding
share of Transmeta’s common stock, subject to working capital and other
adjustments. The merger is expected to close in the first quarter of
2009.
"As a result of our successful licensing activities, we collected $116.5
million of cash payments for our intellectual property and patents in
the third quarter, bringing our yearly total to $266.5 million,” said
Les Crudele, president and CEO. "We also generated additional value for
our stockholders through the transfer of 700,000 shares of Transmeta
Series B Preferred Stock that was held by AMD. After creating such
significant value this year, we are pleased that we are able to return
this value to our stockholders through the impending acquisition by
Novafora.”
Outlook
In the fourth quarter, Transmeta expects to recognize $5.9 million of
operating income from the December 2007 settlement and licensing
agreement with Intel. Transmeta expects to be profitable on a GAAP net
income basis in the fourth quarter of 2008 and continues to expect to be
profitable for fiscal year 2008. The definitive agreement with Novafora
provides, among other things, that Transmeta may not enter into any
future licensing transaction prior to closing of the merger without
Novafora’s consent.
Conference Call
Transmeta has delayed its third quarter earnings conference call,
previously scheduled for today at 5:00 p.m. Eastern time/2:00 p.m.
Pacific time, to Tuesday, November 18, 2008 at 9:00 a.m. Eastern
time/6:00 a.m. Pacific time. The conference call will be available live
over the Internet at the investor relations section of Transmeta's
website at www.transmeta.com.
To listen to the conference call, please dial (785) 830-1997. A
recording of the conference call will be available for one week,
starting one hour after the completion of the call, until 11:59 p.m.
Pacific time on November 24, 2008. The phone number to access the
recording is (719) 457-0820, and the passcode is 2156284.
About Transmeta Corporation
Transmeta Corporation develops and licenses innovative computing,
microprocessor and semiconductor technologies and related intellectual
property. Founded in 1995, we first became known for designing,
developing and selling our highly efficient x86-compatible
software-based microprocessors, which deliver a balance of low power
consumption, high performance, low cost and small size suited for
diverse computing platforms. We are presently focused on developing and
licensing our advanced power management technologies for controlling
leakage and increasing power efficiency in semiconductor and computing
devices, and in licensing our computing and microprocessor technologies
to other companies. To learn more about Transmeta, visit www.transmeta.com.
Safe Harbor Statement
This release contains forward-looking statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995, including those concerning Transmeta’s revenue, the value of
Transmeta’s intellectual property and technologies, the amount of cash
consideration to be received by Transmeta stockholders, the timing and
likelihood of closing of the proposed merger and the potential benefits
of the proposed merger. Such statements speak only as of the date of
this release, and we will not necessarily provide updates of our
projections or other forward-looking statements. Investors are cautioned
that such forward-looking statements are subject to many risks and
uncertainties, and may differ materially or adversely from actual
results or future events. These risks and uncertainties include, among
others, the satisfaction of closing conditions to the proposed merger,
failure of Transmeta stockholders to approve the proposed merger,
Transmeta’s estimates of its operating costs prior to closing the
proposed merger, costs related to the proposed merger, general economic
and political conditions in the U.S. and abroad, and other risks
affecting Transmeta’s and Novafora’s respective businesses generally,
including, with respect to Transmeta, those risks discussed in our most
recent reports on Forms 10-K and 10-Q. We undertake no obligation to
revise or update publicly any forward-looking statement for any reason.
Transmeta and LongRun2 are trademarks of Transmeta Corporation. All
other product or service names mentioned herein are the trademarks of
their respective owners.
Additional Information and Where to Find It
Transmeta will file a proxy statement with the SEC in connection with
the proposed merger. Investors and stockholders of Transmeta are urged
to read the proxy statement and any other relevant documents filed with
the SEC when they become available because they will contain important
information regarding Novafora, Transmeta, the proposed merger, the
persons soliciting proxies in connection with the proposed merger on
behalf of Transmeta and the interests of those persons in the proposed
merger and related matters. Transmeta intends to mail the proxy
statement to its stockholders as soon as practicable. Investors and
stockholders will be able to obtain a copy of the proxy statement and
other documents filed by Transmeta with the SEC free of charge at the
Web site maintained by the SEC at http://www.sec.gov.
In addition, documents filed with the SEC by Transmeta are available
free of charge by contacting Transmeta Investor Relations (Kristine
Mozes, 781-652-8875).
Participants in Solicitation
Transmeta, and its directors, executive officers, and employees may be
deemed to be participants in the solicitation of proxies from the
stockholders of Transmeta in connection with the proposed merger and
related items. Information regarding the directors and executive
officers of Transmeta and their ownership of Transmeta stock is set
forth in Transmeta’s proxy statement for Transmeta’s 2008 annual meeting
of stockholders, which was filed with the SEC on August 25, 2008.
Investors and stockholders may obtain additional information regarding
the interests of those participants by reading the proxy statement
relating to the proposed merger when it becomes available. Investors and
stockholders can obtain a copy of that proxy statement free of charge at
the Web site maintained by the SEC at http://www.sec.gov.
|
Transmeta Corporation
|
|
|
Condensed Consolidated Balance Sheets
|
|
|
(In thousands)
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2008
|
|
December 31, 2007
|
|
September 30, 2007
|
|
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
205,271
|
|
|
$
|
15,607
|
|
|
$
|
19,629
|
|
|
Short-term investments
|
|
|
49,969
|
|
|
|
2,968
|
|
|
|
8,976
|
|
|
Accounts receivable
|
|
|
2
|
|
|
|
163
|
|
|
|
45
|
|
|
Other receivables, current
|
|
|
-
|
|
|
|
149,400
|
|
|
-
|
|
|
Prepaid expenses and other current assets
|
|
|
1,963
|
|
|
|
2,476
|
|
|
|
2,332
|
|
|
Total current assets
|
|
|
257,205
|
|
|
|
170,614
|
|
|
|
30,982
|
|
|
|
|
|
|
|
|
|
|
|
Other receivables, long-term
|
|
|
-
|
|
|
|
85,200
|
|
|
|
-
|
|
|
Property and equipment, net
|
|
|
194
|
|
|
|
284
|
|
|
|
376
|
|
|
Patents and patent rights, net
|
|
|
-
|
|
|
|
2,388
|
|
|
|
4,100
|
|
|
Other assets
|
|
|
200
|
|
|
|
800
|
|
|
|
1,010
|
|
|
TOTAL ASSETS
|
|
$
|
257,599
|
|
|
$
|
259,286
|
|
|
$
|
36,468
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
Current Liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
1,029
|
|
|
$
|
341
|
|
|
$
|
2,171
|
|
|
Accrued compensation
|
|
|
774
|
|
|
|
15,351
|
|
|
|
834
|
|
|
Income taxes payable
|
|
|
15
|
|
|
|
3,306
|
|
|
|
4
|
|
|
Accrued restructuring costs
|
|
|
352
|
|
|
|
1,592
|
|
|
|
2,592
|
|
|
Other accrued liabilities
|
|
|
473
|
|
|
|
1,028
|
|
|
|
4,384
|
|
|
Current portion of deferred income from settlement and licensing
|
|
|
23,460
|
|
|
|
23,460
|
|
|
|
-
|
|
|
Current portion of long-term payable
|
|
|
800
|
|
|
|
667
|
|
|
|
600
|
|
|
Total current liabilities
|
|
|
26,903
|
|
|
|
45,745
|
|
|
|
10,585
|
|
|
|
|
|
|
|
|
|
|
|
Long-term deferred income from settlement and licensing, net of
current portion
|
|
|
193,545
|
|
|
|
211,140
|
|
|
|
-
|
|
|
Long-term payable, net of current portion
|
|
|
200
|
|
|
|
800
|
|
|
|
1,000
|
|
|
Total liabilities
|
|
|
220,648
|
|
|
|
257,685
|
|
|
|
11,585
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity:
|
|
|
|
|
|
|
|
|
Convertible preferred stock
|
|
|
6,966
|
|
|
|
6,966
|
|
|
|
6,966
|
|
|
Common stock
|
|
|
743,641
|
|
|
|
739,268
|
|
|
|
738,625
|
|
|
Treasury stock
|
|
|
(2,439
|
)
|
|
|
(2,439
|
)
|
|
|
(2,439
|
)
|
|
Accumulated other comprehensive gain (loss)
|
|
|
190
|
|
|
|
29
|
|
|
|
29
|
|
|
Accumulated deficit
|
|
|
(711,407
|
)
|
|
|
(742,223
|
)
|
|
|
(718,298
|
)
|
|
Total stockholders' equity
|
|
|
36,951
|
|
|
|
1,601
|
|
|
|
24,883
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
$
|
257,599
|
|
|
$
|
259,286
|
|
|
$
|
36,468
|
|
|
Transmeta Corporation
|
|
Condensed Consolidated Statements of Operations
|
|
(Dollars in thousands, except per share data)
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
|
|
September 30, 2008
|
|
June 30, 2008
|
|
September 30, 2007
|
|
|
September 30, 2008
|
|
September 30, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
$
|
253
|
|
|
$
|
167
|
|
|
|
License
|
|
|
25,299
|
|
|
|
366
|
|
|
|
1
|
|
|
|
|
25,905
|
|
|
|
1
|
|
|
|
Service
|
|
|
-
|
|
|
|
-
|
|
|
|
43
|
|
|
|
|
168
|
|
|
|
2,186
|
|
|
|
|
Total revenue
|
|
|
25,299
|
|
|
|
366
|
|
|
|
44
|
|
|
|
|
26,326
|
|
|
|
2,354
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
3
|
|
|
|
80
|
|
|
|
Service (1)
|
|
|
-
|
|
|
|
-
|
|
|
|
18
|
|
|
|
|
163
|
|
|
|
1,236
|
|
|
|
Impairment charge on inventories
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
-
|
|
|
|
364
|
|
|
|
|
Total cost of revenue
|
|
|
-
|
|
|
|
-
|
|
|
|
18
|
|
|
|
|
166
|
|
|
|
1,680
|
|
|
Gross profit (loss)
|
|
|
25,299
|
|
|
|
366
|
|
|
|
26
|
|
|
|
|
26,160
|
|
|
|
674
|
|
|
Gross margin %
|
|
|
100.0
|
%
|
|
|
100.0
|
%
|
|
|
59.1
|
%
|
|
|
|
99.4
|
%
|
|
|
28.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from settlement and licensing
|
|
|
(5,865
|
)
|
|
|
(5,865
|
)
|
|
|
-
|
|
|
|
|
(17,595
|
)
|
|
|
-
|
|
|
|
Income from license and receivable
|
|
|
(2,855
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
(2,855
|
)
|
|
|
-
|
|
|
|
Research and development (1)
|
|
|
1,586
|
|
|
|
2,315
|
|
|
|
1,336
|
|
|
|
|
6,751
|
|
|
|
8,809
|
|
|
|
Selling, general and administrative (1)
|
|
|
3,700
|
|
|
|
4,108
|
|
|
|
6,107
|
|
|
|
|
12,150
|
|
|
|
17,857
|
|
|
|
Restructuring charges, net
|
|
|
(97
|
)
|
|
|
455
|
|
|
|
177
|
|
|
|
|
700
|
|
|
|
8,878
|
|
|
|
Amortization of patents and patent rights
|
|
|
-
|
|
|
|
908
|
|
|
|
1,711
|
|
|
|
|
2,388
|
|
|
|
5,134
|
|
|
|
Impairment charge on long-lived and other assets
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
-
|
|
|
|
302
|
|
|
|
|
Total operating expenses
|
|
|
(3,531
|
)
|
|
|
1,921
|
|
|
|
9,331
|
|
|
|
|
1,539
|
|
|
|
40,980
|
|
|
Operating loss
|
|
|
28,830
|
|
|
|
(1,555
|
)
|
|
|
(9,305
|
)
|
|
|
|
24,621
|
|
|
|
(40,306
|
)
|
|
|
Interest income and other, net
|
|
|
1,813
|
|
|
|
1,769
|
|
|
|
250
|
|
|
|
|
6,197
|
|
|
|
1,109
|
|
|
|
Interest (expense)
|
|
|
-
|
|
|
|
-
|
|
|
|
(15
|
)
|
|
|
|
(2
|
)
|
|
|
(53
|
)
|
|
Income (loss) before income taxes
|
|
|
30,643
|
|
|
|
214
|
|
|
|
(9,070
|
)
|
|
|
|
30,816
|
|
|
|
(39,250
|
)
|
|
|
Provision for income taxes
|
|
|
-
|
|
|
|
-
|
|
|
|
3
|
|
|
|
|
-
|
|
|
|
7
|
|
|
Net income (loss)
|
|
$
|
30,643
|
|
|
$
|
214
|
|
|
$
|
(9,073
|
)
|
|
|
$
|
30,816
|
|
|
$
|
(39,257
|
)
|
|
|
Deemed dividend for beneficial conversion feature of preferred stock
|
|
|
-
|
|
|
|
-
|
|
|
|
(3,630
|
)
|
|
|
|
-
|
|
|
|
(3,630
|
)
|
|
Net income (loss) attributable to common shareholders
|
|
$
|
30,643
|
|
|
$
|
214
|
|
|
$
|
(12,703
|
)
|
|
|
$
|
30,816
|
|
|
$
|
(42,887
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share attributable to common shareholders -
basic
|
|
$
|
2.52
|
|
|
$
|
0.02
|
|
|
$
|
(1.24
|
)
|
|
|
$
|
2.54
|
|
|
$
|
(4.26
|
)
|
|
Net income (loss) per share attributable to common shareholders -
fully diluted
|
|
$
|
2.31
|
|
|
$
|
0.02
|
|
|
$
|
(1.24
|
)
|
|
|
$
|
2.33
|
|
|
$
|
(4.26
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding - basic
|
|
|
12,170
|
|
|
|
12,152
|
|
|
|
10,236
|
|
|
|
|
12,145
|
|
|
|
10,066
|
|
|
Weighted average shares outstanding - diluted
|
|
|
13,265
|
|
|
|
13,242
|
|
|
|
10,236
|
|
|
|
|
13,220
|
|
|
|
10,066
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Includes stock-based compensation:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of service revenue
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
1
|
|
|
|
$
|
82
|
|
|
$
|
18
|
|
|
Research and development
|
|
|
156
|
|
|
|
596
|
|
|
|
(271
|
)
|
|
|
|
1,599
|
|
|
|
11
|
|
|
Selling, general and administrative
|
|
|
731
|
|
|
$
|
684
|
|
|
$
|
244
|
|
|
|
|
2,047
|
|
|
|
941
|
|